GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » EV-to-EBIT

Kimia Biosciences (BOM:530313) EV-to-EBIT : (As of Oct. 31, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kimia Biosciences's Enterprise Value is ₹2,258.24 Mil. Kimia Biosciences does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Kimia Biosciences's EV-to-EBIT at this moment.

The historical rank and industry rank for Kimia Biosciences's EV-to-EBIT or its related term are showing as below:

BOM:530313's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 17.615
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Kimia Biosciences's Enterprise Value for the quarter that ended in . 20 was ₹0.00 Mil. Kimia Biosciences does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Kimia Biosciences's Earnings Yield (Joel Greenblatt) % at this moment.


Kimia Biosciences EV-to-EBIT Historical Data

The historical data trend for Kimia Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences EV-to-EBIT Chart

Kimia Biosciences Annual Data
Trend
EV-to-EBIT

Kimia Biosciences Semi-Annual Data
EV-to-EBIT

Competitive Comparison of Kimia Biosciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Kimia Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kimia Biosciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kimia Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kimia Biosciences's EV-to-EBIT falls into.



Kimia Biosciences EV-to-EBIT Calculation

Kimia Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2258.237/
=


Kimia Biosciences  (BOM:530313) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Kimia Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 ) =EBIT / Enterprise Value (Q: . 20 )
=/
= %


Kimia Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences Headlines

No Headlines